Galo Duque

Dr. Galo Duque

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022 in Clinical Medicine Insights: Oncology
Verified
Journal Article
Open access
GDGalo Duque
Galo Duque
CMCarlos Manterola
Carlos Manterola
TOTamara Otzen
Tamara Otzen
CACristina Arias
Cristina Arias
DPDennise Palacios
Dennise Palacios
LALorena Carlota Albarracin
Lorena Carlota Albarracin
Background: Breast cancer (BC) is the most common neoplasm in women worldwide. Liquid biopsy (LB) is a non-invasive diagnostic technique that allows the analysis of biomarkers in different body fluids, particularly in peripheral blood and also in urine, saliva, nipple discharge, volatile respiratory fluids, nasal secretions, breast milk, and tears. The objective was to analyze the available evidence related to the use of biomarkers obtained by LB for the early diagnosis of BC. Methods: Articles related to the use of biomarkers for the early diagnosis of BC due to LB, published between 2010 and 2022, from the databases (WoS, EMBASE, PubMed, and SCOPUS) were included. The MInCir diagnostic scale was applied in the articles to determine their methodological quality (MQ). Descriptive statistics were used, as well as determination of weighted averages of each variable, to analyze the extracted data. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) are described. Results: In this systematic review (SR), 136 articles met the selection criteria, representing 17 709 patients with BC. However, 95.6% were case-control studies. In 96.3% of cases, LB was performed in peripheral blood samples. Most of the articles were based on microRNA (miRNA) analysis. The mean MQ score was 25/45 points. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) have been found. Conclusions: The determination of biomarkers through LB is a useful mechanism for the diagnosis of BC. The analysis of miRNA in peripheral blood is the most studied methodology. Our results indicate that LB has a high sensitivity and specificity for the diagnosis of BC, especially in early stages.

23 October 2021 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
GDGalo Duque
Galo Duque
CMCarlos Manterola
Carlos Manterola
TOTamara Otzen
Tamara Otzen
CACristina Arias
Cristina Arias
BGBryan Galindo
Bryan Galindo
NGNayeli García
Nayeli García

1 November 2019 in HPB
Verified
Journal Article
Closed access
CMCarlos Manterola
Carlos Manterola
GDGalo Duque
Galo Duque
LGLuis Grande
Luis Grande
XAXabier de Aretxabala
Xabier de Aretxabala
RCRoque Conejeros
Roque Conejeros
NGNayely García
Nayely García

1 November 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
LALorena Albarracín-Navas
Lorena Albarracín-Navas
MAMAYLIN ALMONTE ALMONTE-BECERRIL
MAYLIN ALMONTE ALMONTE-BECERRIL
EGEnmanuel Guerrero
Enmanuel Guerrero
JRJosue Rivadeneira
Josue Rivadeneira
MTMARCELINO TELECHEA
MARCELINO TELECHEA
ARAngela L. Riffo-Campos
Angela L. Riffo-Campos
Background: Prostate cancer is the second most common neoplasm in men, with projections estimating over one million new cases by 2045. Differentially expressed genes can significantly enhance the diagnosis, treatment, monitoring, and prognosis of this disease. Purpose: to systematically review and analyze validated differentially expressed mRNAs in prostate cancer patients to propose a robust molecular profile for clinical diagnostics. Methods: A systematic review was conducted following PRISMA guidelines, searching literature databases for mRNAs with validated differential expression in adult prostate cancer patients. Identified mRNAs were analyzed using STRING, Cytoscape, and DrugBank to explore protein–protein interactions and potential drug targets. Results: A total of 5003 participants from Europe, Asia, America, and Oceania were included, and 144 mRNAs (p < 0.05) were reported across 75 primary articles, predominantly validated using RT-qPCR with tissue samples. Among these, at least 36 mRNAs were identified as targets for cancer-related drugs. Enrichment analysis revealed the top pathways were associated with cancer, including specific prostate cancer terms. Key nodes emerged as hubs in the protein–protein interaction network. Conclusion: Based on our comprehensive in silico analysis of validated differentially expressed mRNAs, we propose a molecular profile of twenty-five mRNAs with significant potential for clinical diagnosis of prostate cancer. These findings offer a valuable foundation for developing precision oncology strategies to improve patient outcomes.

1 November 2015 in Revista Médica Hospital del José Carrasco Arteaga
Verified
Journal Article
Open access
PDF file
SFSantiago Alejandro Mejía Freire
Santiago Alejandro Mejía Freire
ACAndrés Alejandro Molina Calderón
Andrés Alejandro Molina Calderón
GDGalo Duque
Galo Duque
FMFernando Arias Maldonado
Fernando Arias Maldonado
Estudio Descriptivo: Características Clínicas, Demográficas e Histopatológicas de Pacientes con Diagnóstico de Linfoma no Hodgkin.

31 July 2018 in Revista Médica Hospital del José Carrasco Arteaga
Verified
Journal Article
Closed access
PDF file
MJMaría Paz Orellana Jara
María Paz Orellana Jara
JGJuana Carolina Cordero Garate
Juana Carolina Cordero Garate
GDGalo Duque
Galo Duque
BACKGROUND: Prostate cancer is the fifth most common neoplasms worldwide and the second in man. In Cuenca, according to the sixth epidemiology of cancer, it is the second cause of death in males. METHODS: Observational descriptive study the sample was for convenience, made up with 315 patients with positive biopsy. The established variables were: Signs and symptoms, histopathological type, total prostate specific antigen (PSA) measure, risk factors, Gleason score, differentiation grade and clinical staging. The media and median were obtained as the crossing of variables using Pearson and Spearman correlation coefficient. The software used was STATA 12 version. RESULTS: The most common symptoms were urinary frequency (56.2 %) and dysuria (36.8 %). 312 patients presented adenocarcinoma as histopathology type. The total PSA had a median of 4.4 ng/ml and a media of 34 ng/ml. The media of age was 69 years old. 141 patients presented hypertension. About the Gleason Grading system most of people were moderately differentiated (43.6 %). 67 % of cases were diagnosed during stages I and II. The Rho correlation coefficient was 0.44 between clinical stage and Gleason score; it was of 0.36 between PSA and clinical stage. CONCLUSIONS: It was found a moderately positive association between clinical stage and Gleason score. There is no minimal measure of total PSA that could assure us there is no risk of prostate cancer. More prospective studies are needed in order to find the relation between prostate cancer and risk factors.